Host-pathogen interplay in the respiratory environment of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 14, Issue 4, 2015, Pages 431-439

  Yonker, Lael M ^a   Cigana, Cristina ^b   Hurley, Bryan P ^a   Bragonzi, Alessandra ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cystic fibrosis; Host pathogen interaction; Innate and adaptive immunity; Lung disease; Microbiota

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; CORTICOSTEROID; DEOXYRIBONUCLEASE; IBUPROFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADAPTIVE IMMUNITY; ANTIBIOTIC THERAPY; BIOFILM; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; EXTRACELLULAR TRAP; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LUNG FIBROSIS; LUNG FLORA; MACROPHAGE; MICROBIAL COLONIZATION; MICROFLORA; NEUTROPHIL; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; RESPIRATORY SYSTEM; REVIEW; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT INFECTIONS;

ADAPTIVE IMMUNITY; CYSTIC FIBROSIS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 84937638768     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.02.008     Document Type: Review

References (104)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(8):918-951.
2. Lipuma J. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010, 23(2):299-323.
3. Bevivino A., Bragonzi A. The evolving polymicrobial composition in the airways of patients with cystic fibrosis: implications for disease progression and clinical management. CML - Cyst Fibros 2013, 3(4):93-104.
4. Armstrong D., Grimwood K., Carlin J.B., Carzino R., Gutierrez J.P., Hull J., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
5. Kahl B. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol 2010, 300(8):514-519.
6. Beck J.M., Young V.B., Huffnagle G.B. The microbiome of the lung. Transl Res 2012, 160(4):258-266.
7. Madan J., Koestler D.C., Stanton B.A., Davidson L., Moulton L.A., Housman M.L., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012, 21(3):4.
8. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011, 24:390-395.
9. Cigana C., Lorè N.I., Bernardini M.L., Bragonzi A. Dampening host sensing and avoiding recognition in Pseudomonas aeruginosa pneumonia. J Biomed Biotechnol 2011, 852513.
10. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
11. Tavs Q., Pressler Tania, Høiby Niels, Katzenstein Terese L. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res 2014, 15(1):41.
12. Amin R., Dupuis A., Aaron S.D., Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010, 137(1):171-176.
13. Surette M. The cystic fibrosis lung microbiome. Ann Am Thorac Soc 2014, (Suppl. 1):S61-S65.
14. Conrad D., Haynes M., Salamon P., Rainey P.B., Youle M., Rohwer F. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol 2013, 48(2):150-156.
15. Brown P., Pope C.E., Marsh R.L., Qin X., McNamara S., Gibson R., et al. Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc 2014, 11(7):1049-1055.
16. Cox M.J., Allgaier M., Taylor B., Baek M.S., Huang Y.J., Daly R.A., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010, 5:e11044.
17. Zhao J., Schloss P.D., Kalikin L.M., Carmody L.A., Foster B.K., Petrosino J.F., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012, 109:5809-5814.
18. Rieber N., Hector A., Carevic M., Hartl D. Current concepts of immune dysregulation in cystic fibrosis. Int J Biochem Cell Biol 2014, 52:108-112.
19. Button B., Cai L.H., Ehre C., Kesimer M., Hill D.B., Sheehan J.K., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012, 337(6097):937-941.
20. Boucher R.C. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007, 13(6):231-240.
21. Skerrett S.J., Wilson C.B., Liggitt H.D., Hajjar A.M. Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2007, 292(1):L312-L322.
22. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336(15):1066-1071.
23. John G., Yildirim A.O., Rubin B.K., Gruenert D.C., Henke M.O., et al. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. Am J Respir Cell Mol Biol 2010, 42(4):424-431.
24. Venkatakrishnan A., Stecenko A.A., King G., Blackwell T.R., Brigham K.L., Christman J.W., et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000, 23(3):396-403.
25. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133(2):489-495.
26. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1425-1431.
27. Burns A.R., Smith C.W., Walker D.C. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003, 83(2):309-336.
28. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008, 180(8):5662-5669.
29. Snelgrove R.J., Jackson P.L., Hardison M.T., Noerager B.D., Kinloch A., Gaggar A., et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330(6000):90-94.
30. Lämmermann T., Afonso P.V., Angermann B.R., Wang J.M., Kastenmüller W., Parent C.A., et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 2013, 498(7454):371-375.
31. Pazos M.A., Pirzai W., Yonker L.M., Morisseau C., Gronert K., Hurley B.P. Distinct cellular sources of hepoxilin a3 and leukotriene b4 are used to coordinate bacterial-induced neutrophil transepithelial migration. J Immunol 2015, 194(3):1304-1315.
32. Bodini A., D'Orazio C., Peroni D., Corradi M., Folesani G., Baraldi E., et al. Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections. Pediatr Pulmonol 2005, 40(6):494-499.
33. Tamang D.L., Pirzai W., Priebe G.P., Traficante D.C., Pier G.B., Falck J.R., et al. Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol 2012, 189(10):4960-4969.
34. Hurley B.P., Sin A., McCormick B.A. Adhesion molecules involved in hepoxilin A3-mediated neutrophil transepithelial migration. Clin Exp Immunol 2008, 151(2):297-305.
35. Klesney-Tait J., Keck K., Li X., Gilfillan S., Otero K., Baruah S., et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest 2013, 123(1):138-149.
36. Sly P.D., Gangell C.L., Chen L., Ware R.S., Ranganathan S., Mott L.S., et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013, 368(21):1963-1970.
37. Gifford A.M., Chalmers J.D. The role of neutrophils in cystic fibrosis. Curr Opin Hematol 2014, 21(1):16-22.
38. Parsek M.R., Tolker-Nielsen T. Pattern formation in Pseudomonas aeruginosa biofilms. Curr Opin Microbiol 2008, 11(6):560-566.
39. Elias S., Banin E. Multi-species biofilms: living with friendly neighbors. FEMS Microbiol Rev 2012, 36(5):990-1004.
40. Bjarnsholt T., Jensen P.Ø., Burmølle M., Hentzer M., Haagensen J.A., Hougen H.P., et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005, 151(Pt 2):373-383.
41. Donlan R.M., Costerton J.W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002, 15(2):167-193.
42. Chiang W.C., Nilsson M., Jensen P.Ø., Høiby N., Nielsen T.E., Givskov M., et al. Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013, 57(5):2352-2361.
43. Zimmermann S., Wagner C., Müller W., Brenner-Weiss G., Hug F., Prior B., et al. Induction of neutrophil chemotaxis by the quorum-sensing molecule N-(3-oxododecanoyl)-l-homoserine lactone. Infect Immun 2006, 74(10):5687-5692.
44. Trevani A.S., Chorny A., Salamone G., Vermeulen M., Gamberale R., Schettini J., et al. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 2003, 33(11):3164-3174.
45. Jesaitis A.J., Franklin M.J., Berglund D., Sasaki M., Lord C.I., Bleazard J.B., et al. Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J Immunol 2003, 171(8):4329-4339.
46. Jensen P.O., Bjarnsholt T., Phipps R., Rasmussen T.B., Calum H., Christoffersen L., et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007, 153(Pt 5):1329-1338.
47. Alhede M., Bjarnsholt T., Jensen P.Ø., Phipps R.K., Moser C., Christophersen L., et al. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology 2009, 155(Pt 11):3500-3508.
48. Walker T.S., Tomlin K.L., Worthen G.S., Poch K.R., Lieber J.G., Saavedra M.T., et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005, 73(6):3693-3701.
49. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535.
50. Hakkim A., Fuchs T.A., Martinez N.E., Hess S., Prinz H., Zychlinsky A., et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 2011, 7(2):75-77.
51. Fuchs T.A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176(2):231-241.
52. Farley K., Stolley J.M., Zhao P., Cooley J., Remold-O'Donnell E., et al. A serpinB1 regulatory mechanism is essential for restricting neutrophil extracellular trap generation. J Immunol 2012, 189(9):4574-4581.
53. Benarafa C., Priebe G.P., Remold-O'Donnell E. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med 2007, 204(8):1901-1909.
54. Yoo D.G., Floyd M., Winn M., Moskowitz S.M., Rada B. NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes. Immunol Lett 2014, 160(2):186-194.
55. Rada B., Jendrysik M.A., Pang L., Hayes C.P., Yoo D.G., Park J.J., et al. Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS One 2013, 8(1):e54205.
56. Young R.L., Malcolm K.C., Kret J.E., Caceres S.M., Poch K.R., Nichols D.P., et al. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One 2011, 6(9):e23637.
57. Khatua B., Bhattacharya K., Mandal C. Sialoglycoproteins adsorbed by Pseudomonas aeruginosa facilitate their survival by impeding neutrophil extracellular trap through siglec-9. J Leukoc Biol 2012, 91(4):641-655.
58. Thammavongsa V., Missiakas D.M., Schneewind O. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 2013, 342(6160):863-866.
59. Langereis J.D., Hermans P.W. Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett 2013, 346(2):81-89.
60. Rahman S., Gadjeva M. Does NETosis contribute to the bacterial pathoadaptation in cystic fibrosis?. Front Immunol 2014, 5:378.
61. Hartl D., Gaggar A., Bruscia E., Hector A., Marcos V., Jung A., Greene C., et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012, 11(5):363-382.
62. Del Porto P., Cifani N., Guarnieri S., Di Domenico E.G., Mariggiò M.A., Spadaro F., et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One 2011, 6(5):e19970.
63. Bruscia E., Zhang P.X., Ferreira E., Caputo C., Emerson J.W., Tuck D., et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am J Respir Cell Mol Biol 2009, 40(3):295-304.
64. Di A., Brown M.E., Deriy L.V., Li C., Szeto F.L., Chen Y., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8(9):933-944.
65. Haggie P.M., Verkman A.S. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007, 282(43):31422-31428.
66. Bruscia E.M., Zhang P.X., Satoh A., Caputo C., Medzhitov R., Shenoy A., et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 2011, 186:6990-6998.
67. Bianchi S.M., Prince L.R., McPhillips K., Allen L., Marriott H.M., Taylor G.W., et al. Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2008, 177(1):35-43.
68. Dong Y.J., Chao A.C., Kouyama K., Hsu Y.P., Bocian R.C., Moss R.B., et al. Activation of CFTR chloride current by nitric oxide in human T lymphocytes. EMBO J 1995, 14(12):2700-2707.
69. Agarwal R., Khan A., Aggarwal A.N., Gupta D. Link between CFTR mutations and ABPA: a systematic review and meta-analysis. Mycoses 2012, 55(4):357-365.
70. Mueller C., Braag S.A., Keeler A., Hodges C., Drumm M., Flotte T.R. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011, 44(6):922-929.
71. Knutsen A.P., Hutchinson P.S., Albers G.M., Consolino J., Smick J., Kurup V.P. Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy 2004, 59(1):81-87.
72. Moss R.B., Hsu Y.P., Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000, 120(3):518-525.
73. Cenci E., Mencacci A., Del Sero G., Bacci A., Montagnoli C., d'Ostiani C.F., et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999, 180(6):1957-1968.
74. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37(10):2695-2706.
75. Al Alam D., Deslee G., Tournois C., Lamkhioued B., Lebargy F., Merten M., et al. Impaired interleukin-8 chemokine secretion by staphylococcus aureus-activated epithelium and T-cell chemotaxis in cystic fibrosis. Am J Respir Cell Mol Biol 2010, 42(6):644-650.
76. Tiringer K., Treis A., Fucik P., Gona M., Gruber S., Renner S., et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013, 187(6):621-629.
77. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117(1):204-211.
78. Moser C., Kjaergaard S., Pressler T., Kharazmi A., Koch C., Høiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 2000, 108(5):329-335.
79. Wojnarowski C., Frischer T., Hofbauer E., Grabner C., Mosgoeller W., Eichler I., et al. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation 1999, 14(5):1136-1144.
80. Moser C., Jensen P.Ø., Kobayashi O., Hougen H.P., Song Z., Rygaard J., et al. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 2002, 127(2):206-213.
81. Decraene A., Willems-Widyastuti A., Kasran A., De Boeck K., Bullens D.M., Dupont L.J. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res 2010, 11:177.
82. Chan Y.R., Chen K., Duncan S.R., Lathrop K.L., Latoche J.D., Logar A.J., et al. Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol 2013, 131:1117-1129.
83. Amin P.B., Diebel L.N., Liberati D.M. Secretory immunoglobulin A abrogates inflammatory responses and improves mortality after Pseudomonas pneumonia. J Trauma 2010, 68(4):827-833.
84. Doring G., Meisner C., Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007, 104(26):11020-11025.
85. Johansen H.K., Gotzsche P.C. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013, 6:CD001399.
86. Fuxman Bass J.I., Russo D.M., Gabelloni M.L., Geffner J.R., Giordano M., Catalano M., et al. Extracellular DNA: a major proinflammatory component of Pseudomonas aeruginosa biofilms. J Immunol 2010, 184(11):6386-6395.
87. Konstan M.W., Krenicky J.E., Finney M.R., Kirchner H.L., Hilliard K.A., Hilliard J.B., et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003, 306(3):1086-1091.
88. Lands L.C., Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007, 4:CD001505.
89. Bertolotto M., Contini P., Ottonello L., Pende A., Dallegri F., Montecucco F. Neutrophil migration towards C5a and CXCL8 is prevented by non-steroidal anti-inflammatory drugs via inhibition of different pathways. Br J Pharmacol 2014, 171(14):3376-3393.
90. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756.
91. Drago L., De Vecchi E., Mattina R., Romano C.L. Activity of N-acetyl-l-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013, 36(1):39-46.
92. Sprenger L., Goldmann T., Vollmer E., Steffen A., Wollenberg B., Zabel P., et al. Dexamethasone and N-acetyl-cysteine attenuate Pseudomonas aeruginosa-induced mucus expression in human airways. Pulm Pharmacol Ther 2011, 24(2):232-239.
93. Kirchner T., Hermann E., Moller S., Klinger M., Solbach W., Laskay T., et al. Flavonoids and 5-aminosalicylic acid inhibit the formation of neutrophil extracellular traps. Mediators Inflamm 2013, 2013:710239.
94. Conrad C., Lymp J., Thompson V., Dunn C., Davies Z., Chatfield B., et al. Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros 2014.
95. van Overveld F.J., Demkow U.A., Gorecka D., Zielinski J., De Backer W.A. Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. Eur J Pharmacol 2003, 477(3):261-267.
96. Eigen H., Rosenstein B.J., FitzSimmons S., Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995, 126(4):515-523.
97. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
98. Konstan M.W., Doring G., Heltshe S.L., Lands L.C., Hilliard K.A., Koker P., et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014, 13(2):148-155.
99. Doring G., Bragonzi A., Paroni M., Akturk F.F., Cigana C., Schmidt A., et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 2014, 13(2):156-163.
100. http://www.cff.org/research/DrugDevelopmentPipeline/.
101. Pott G.B., Beard K.S., Bryan C.L., Merrick D.T., Shapiro L. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health 2013, 1:19.
102. Martin S.L., Downey D., Bilton D., Keogan M.T., Edgar J., Elborn J.S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006, 41(2):177-183.
103. Francois B., Luyt C.E., Dugard A., Wolff M., Diehl J.L., Jaber S., et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012, 40(8):2320-2326.
104. Milla C.E., Chmiel J.F., Accurso F.J., VanDevanter D.R., Konstan M.W., Yarranton G., et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2014, 49(7):650-658.